clinical trial · NCT05802173
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Alopecia, AndrogeneticTDM-105795, 0.0025%TDM-105795, 0.02%TDM-105795 topical vehicle solution
brief summary
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
started
Mar 6, 2023
primary completion
Nov 8, 2023
completion
Jan 29, 2024
last updated
Nov 12, 2025
detailed description
Protocol 239-11651-203 is a Phase 2 study entitled "A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia" Eligible subjects will be randomized (1:1:1) to 1 of the 3 groups (low dose vs high dose vs placebo) and treated for 16 weeks.
official title
A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects With Androgenetic Alopecia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol